ReviewPharmaceuticals (Basel, Switzerland)2021
Probiotics in Intestinal Mucosal Healing: A New Therapy or an Old Friend?
Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Restoration of the Mucosal Barrier by Lactobacillus gasseri HDS0266 and Enterococcus faecium HDS0288 in Dextran Sodium Sulfate and Clostridioides difficile-Induced Colitis Mice.Probiotics and antimicrobial proteins · 2026Article
- Mucosa-associated bacteria and metabolites in inflammatory bowel disease: from inside to insight.NPJ biofilms and microbiomes · 2026Review
- Probiotics as eco-friendlybio-preservatives: In vivo mechanisms of mycotoxin inhibition and emerging applications for food safety and human health.Mycotoxin research · 2025Review
- Impact of gut microbiome on outcomes following endoscopic interventions in gastrointestinal disease.World journal of gastrointestinal endoscopy · 2025Article
- Evaluation ofFood science & nutrition · 2025Article
- Ulcerative colitis: the healing power of macrophages.Tissue barriers · 2025Review
- Changes in amino acid concentrations and the gut microbiota composition are implicated in the mucosal healing of ulcerative colitis and can be used as noninvasive diagnostic biomarkers.Clinical proteomics · 2024Article
- Lactobacillus rhamnosus modulates murine neonatal gut microbiota and inflammation caused by pathogenic Escherichia coli.BMC microbiology · 2024Article
- Christensenella minuta protects and restores intestinal barrier in a colitis mouse model by regulating inflammation.NPJ biofilms and microbiomes · 2024Article
- The Antidiabetic Potential of Probiotics: A Review.Nutrients · 2024Review
- Probiotic Yeasts: A Developing Reality?Journal of fungi (Basel, Switzerland) · 2024Review
- Probiotics: Shaping the gut immunological responses.World journal of gastroenterology · 2024Article
- Special Issue "Gut Microbiota, Inflammatory Bowel Diseases, and Therapeutic Targets".Pharmaceuticals (Basel, Switzerland) · 2023Article
- Role ofNutrients · 2023Article
- The Probiotic Strains Bifidοbacterium lactis, Lactobacillus acidophilus, Lactiplantibacillus plantarum and Saccharomyces boulardii Regulate Wound Healing and Chemokine Responses in Human Intestinal Subepithelial MyofibroblastsPharmaceuticals (Basel, Switzerland) · 2022Article
- Mucosa and microbiota - the role of intrinsic parameters on intestinal wound healing.Frontiers in surgery · 2022Review
- Efficacy and Safety of Probiotics Combined With Traditional Chinese Medicine for Ulcerative Colitis: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis are characterized by chronic and relapsing inflammation, while their pathogenesis remains mostly unelucidated. Gut commensal microbiota seem to be one of the various implicated factors, as several studies have shown a significant decrease in the microbiome diversity of patients with IBD. Although the question of whether microbiota dysbiosis is a causal factor or the result of chronic inflammation remains unanswered, one fact is clear; active inflammation in IBD results in the disruption of the mucus layer structure, barrier function, and also, colonization sites. Recently, many studies on IBD have been focusing on the interplay between mucosal and luminal microbiota, underlining their possible beneficial effect on mucosal healing. Regarding this notion, it has now been shown that specific probiotic strains, when administrated, lead to significantly decreased inflammation, amelioration of colitis, and improved mucosal healing. Probiotics are live microorganisms exerting beneficial effects on the host's health when administered in adequate quantity. The aim of this review was to present and discuss the current findings on the role of gut microbiota and their metabolites in intestinal wound healing and the effects of probiotics on intestinal mucosal wound closure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.